XBIO — Xenetic Biosciences Share Price
0.000.00%
Last trade - 00:00- $4.27m
- -$1.89m
- $2.50m
- 27
- 51
- 10
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.71 | ||
| Price to Tang. Book | 0.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.99% | ||
| Return on Equity | -50.13% | ||
| Operating Margin | -168.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.44 | 1.16 | 1.71 | 2.54 | 2.5 | 2.8 | 2.3 | 171.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Directors
- Jeffrey Eisenberg CEO (55)
- James Parslow CFO (56)
- Curtis Lockshin CSO (61)
- Grigory Borisenko IND (52)
- James Callaway IND (65)
- Firdaus Dastoor IND (68)
- Roger Kornberg IND (74)
- Adam Logal IND (43)
- Alexey Vinogradov IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 9th, 2011
- Public Since
- November 7th, 2016
- No. of Shareholders
- 425
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,542,139
- Address
- 945 Concord St., FRAMINGHAM, 01701
- Web
- https://www.xeneticbio.com/
- Phone
- +1 7817787720
- Contact
- Jenene Thomas
- Auditors
- Marcum LLP
Upcoming Events for XBIO
Q2 2025 Xenetic Biosciences Inc Earnings Release
Similar to XBIO
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Xenetic Biosciences share price?
As of Today at 24:10 UTC, shares in Xenetic Biosciences are trading at $2.77. This share price information is delayed by 15 minutes.
How has the Xenetic Biosciences share price performed this year?
Shares in Xenetic Biosciences last closed at $2.77 and the price had moved by -28.97% over the past 365 days. In terms of relative price strength the Xenetic Biosciences share price has underperformed the S&P500 Index by -35.95% over the past year.
What are the analyst and broker recommendations for Xenetic Biosciences?
The overall consensus recommendation for Xenetic Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Xenetic Biosciences dividend yield?
Xenetic Biosciences does not currently pay a dividend.
Does Xenetic Biosciences pay a dividend?
Xenetic Biosciences does not currently pay a dividend.
When does Xenetic Biosciences next pay dividends?
Xenetic Biosciences does not currently pay a dividend.
How do I buy Xenetic Biosciences shares?
To buy shares in Xenetic Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xenetic Biosciences?
As of the previous close price of $2.77, shares in Xenetic Biosciences had a market capitalisation of $4.27m.
Where are Xenetic Biosciences shares listed?
Here are the trading details for Xenetic Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: XBIO
What kind of share is Xenetic Biosciences?
Based on an overall assessment of its quality, value and momentum Xenetic Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xenetic Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Xenetic Biosciences is $40.00. That is 1344.04% above the last closing price of $2.77.
Analysts covering Xenetic Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.24 for the next financial year.
Find out moreWhat is the trend in the Xenetic Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xenetic Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -32.13%.
As of the last closing price of $2.77, shares in Xenetic Biosciences were trading -26.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xenetic Biosciences PE Ratio?
The Xenetic Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xenetic Biosciences?
Xenetic Biosciences' management team is headed by:
- Jeffrey Eisenberg - CEO
- James Parslow - CFO
- Curtis Lockshin - CSO
- Grigory Borisenko - IND
- James Callaway - IND
- Firdaus Dastoor - IND
- Roger Kornberg - IND
- Adam Logal - IND
- Alexey Vinogradov - IND